For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue | - | 0 | - | 2,733 |
| Research and development | 4,912 | 5,035 | 2,311 | 2,291 |
| General and administrative | 2,034 | 2,333 | 1,744 | 1,691 |
| Total operating expenses | 6,946 | 7,368 | 4,055 | 3,982 |
| Loss from operations | -6,946 | -7,368 | -4,055 | -1,249 |
| Change in fair value of warrant liability | 159 | 89 | 3 | -146 |
| Other income, net | -2 | 14 | 96 | 188 |
| Net (gain) income | -7,107 | -7,443 | -3,962 | -915 |
| Net (loss) income attributable to series c preferred stockholders, basic | - | - | - | -290 |
| Net (gain) income attributable to common stockholders, basic | -5,692 | -4,558 | -3,035 | -625 |
| Basic EPS | -0.53 | -0.554 | -0.34 | -0.11 |
| Diluted EPS | -0.53 | -0.544 | -0.34 | -0.11 |
| Basic Average Shares | 10,640,625 | 8,228,169* | 8,818,859 | 5,820,903 |
| Diluted Average Shares | 10,640,625 | 8,376,380* | 8,818,859 | 5,820,903 |
Traws Pharma, Inc. (TRAW)
Traws Pharma, Inc. (TRAW)